Latest Contract Manufacturing News

Bioxyne Limited projects FY2026 revenue between $65 million and $75 million, driven by expansion in Australian medical cannabis and a landmark $5.8 million contract in Germany.

Tissue Repair Ltd reported a 27.3% revenue increase to $3.22 million for FY25, driven by new distribution deals and regulatory progress, while continuing to invest heavily in clinical trials and manufacturing scale-up, resulting in a $4.24 million loss.

Structural Monitoring Systems plc has reported its first profit after tax, driven by strong avionics sales and a successful $8.7 million capital raise. The company’s strategic shift towards proprietary products and key certifications underpin a positive outlook.

Acrux Ltd reported a 44% revenue decline and a modest increase in net loss for FY25, while expanding its US topical generics portfolio and entering the Saudi Arabian market. The company signals a strategic pivot amid intensifying competition and lower returns.

Australian Dairy Nutritionals Group (ASX, AHF) reported a 14% revenue increase to $7.17 million for FY25, driven by a nearly fourfold surge in its infant formula segment, while reducing its net loss by 29%. The company remains debt-free and is expanding its footprint in China and Vietnam.

Jatcorp Limited reported a $6.9 million net loss for FY25, hit by a trademark dispute in China that suspended key product sales. Despite setbacks, the company is accelerating new channel growth and product innovation to regain momentum.

DroneShield Limited has reported a landmark first half of 2025, with revenue surging 210% to $72.3 million and securing its largest-ever contract worth $61.6 million, setting the stage for a transformative year.

DroneShield Limited has reported a remarkable turnaround in the half-year ended June 2025, posting record revenue of $72.3 million and a profit after tax of $2.1 million, reversing last year’s loss. The company also secured its largest-ever contract, signaling strong momentum in the counterdrone technology sector.

Cleo Diagnostics reported a $4 million loss for FY2025 while making significant strides toward FDA approval of its novel ovarian cancer blood test. The company is progressing clinical trials and scaling manufacturing in preparation for market entry.

Star Combo Pharma has reported a remarkable jump in profit for FY2025, driven by strong revenue growth and a settled insurance claim, while declaring its second dividend and planning production expansion.

Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.

Elsight Limited has reported a remarkable 344% jump in first-half revenue to US$4.85 million, significantly narrowing its net loss and securing a substantial US$39 million capital raise to fuel growth.